All News

The coronavirus disease 2019 (COVID-19) pandemic has led to healthcare cost increases of as much as 7% for employers, based on recent study results, stressing the essential need for organizations to have a plan that supports employees and potential revenue loss.

Amid the coronavirus disease 2019 (COVID-19) pandemic, the American Academy of Sleep Medicine (AASM) has issued a position statement on the significance of sufficient sleep, which when impaired has been deemed a possible contributing factor to physician burnout.

Evolocumab (Repatha), a human monoclonal antibody and proprotein convertase subtilisin/kexin type 9 inhibitor, produced positive results in persons living with HIV in the BEIJERINCK study by reducing their levels of low-density lipoprotein cholesterol (LDL-C). These individuals have a risk of cardiovascular disease that is almost twice that of HIV-negative individuals.

The changes are aimed at helping hospitals increase their capacities for the sickest patients; expand the pool of local healthcare providers who are available to work; eliminating ordinary paperwork and documentation requirements; expanding Medicare coverage for respiratory-related devices and equipment for any medical reason; and expanding telehealth in Medicare by covering more than 80 additional services.

This week, the top managed care news includes a $2 trillion package to address economic damage from coronavirus heads to President Trump, a regulatory change could change the fortunes for biosimilars, and the world’s biggest cardiology meeting goes virtual.

Ovarian cancer remains the most deadly of the gynecologic cancers. Researchers from Dana-Farber Cancer Institute may have discovered biomarkers that could predict which patients with platinum-resistant ovarian cancer would benefit from combination poly-ADP ribose polymerase (PARP) inhibitor/immune checkpoint inhibition treatment, as well as those who should pursue a different course of therapy.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo